0001193125-22-005117.txt : 20220110 0001193125-22-005117.hdr.sgml : 20220110 20220110080857 ACCESSION NUMBER: 0001193125-22-005117 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220110 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220110 DATE AS OF CHANGE: 20220110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CERUS CORP CENTRAL INDEX KEY: 0001020214 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 680262011 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21937 FILM NUMBER: 22519778 BUSINESS ADDRESS: STREET 1: 1220 CONCORD AVENUE STREET 2: SUITE 600 CITY: CONCORD STATE: CA ZIP: 94520 BUSINESS PHONE: 9252886000 MAIL ADDRESS: STREET 1: 1220 CONCORD AVENUE STREET 2: SUITE 600 CITY: CONCORD STATE: CA ZIP: 94520 FORMER COMPANY: FORMER CONFORMED NAME: CERUS TECHNOLOGIES INC DATE OF NAME CHANGE: 19960731 8-K 1 d286874d8k.htm 8-K 8-K
CERUS CORP false 0001020214 0001020214 2022-01-10 2022-01-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 10, 2022

 

 

CERUS CORPORATION

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   000-21937   68-0262011

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

1220 Concord Ave, Suite 600

Concord, California

   94520
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code (925) 288-6000

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   CERS   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition

On January 10, 2022, Cerus Corporation (the “Company”) announced its preliminary product revenue results for the fourth quarter and fiscal year ended December 31, 2021. A copy of the Company’s press release, entitled “Cerus Corporation Announces Record Preliminary Fourth Quarter and Full-Year 2021 Product Revenue and Provides Business Update,” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

Such product revenue results as reported are preliminary, unaudited and subject to completion. The Company’s independent registered public accounting firm has not audited or performed any procedures with respect to these preliminary results and does not express an opinion or any other form of assurance with respect thereto. The Company’s financial closing procedures for the three months and year ended December 31, 2021 are not yet complete and, as a result, the final results upon completion of the closing procedures may vary from the preliminary estimates, and any such differences may be material. The Company’s product revenue information presented herein should not be viewed as a substitute for the information set forth in the full financial statements prepared in accordance with U.S. generally accepted accounting principles, and undue reliance should not be placed on these preliminary product revenue results.

The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01

Financial Statements and Exhibits

(d)    Exhibits.

The following exhibit is furnished with this report:

 

 

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: January 10, 2022     CERUS CORPORATION
    By:  

/s/ Kevin D. Green

      Kevin D. Green
      Vice President, Finance and Chief Financial Officer

 

3

EX-99.1 2 d286874dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Cerus Corporation Announces Record Preliminary Fourth Quarter and Full-Year 2021 Product Revenue and Provides Business Update

Preliminary Q4:21 and Full-Year 2021 Product Revenues of $39.9 million and $130.9 million reflects year-over-year growth of 41% and 42%, respectively

2022 Product Revenues expected to be between $157-164 million, reflecting 20%-25% growth versus 2021

Expanding Access to INTERCEPT Fibrinogen Complex in 2022

January 10, 2022, CONCORD, Calif.—(BUSINESS WIRE)—Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2021, provided product revenue guidance for 2022 and provided an update on its INTERCEPT Blood System for Cryoprecipitation offering, which is used to produce INTERCEPT Fibrinogen Complex.

Cerus’ unaudited preliminary product revenue for the fourth quarter of 2021 totaled $39.9 million, representing an increase of 41% over the $28.2 million recognized during the fourth quarter of 2020. The Company expects its unaudited preliminary full-year 2021 product revenue to be $130.9 million, exceeding the Company’s most recent 2021 product revenue guidance range of $127-$129 million. The preliminary product revenue results have not been audited and are subject to change.

“Cerus’ commercial momentum during the first three quarters of 2021 carried on during the fourth quarter, continuing the Company’s growth trajectory. Strong uptake of INTERCEPT platelets in the fourth quarter of 2021 was again led by U.S. blood center adoption and growing hospital demand. I am pleased to report yet another record quarter and the corresponding positive impact on patient access to INTERCEPT-treated blood components,” stated William “Obi” Greenman, Cerus’ president and chief executive officer. “With the INTERCEPT Blood System for platelets being adopted so rapidly in the U.S. market, I am proud to say that on a run-rate basis, more than half of platelets in the U.S. are now treated with our technology, helping us realize our mission of making pathogen inactivation the standard of care globally. In this age of pandemic preparedness and awareness, we believe 2022 will see a continuation of our positive trajectory and result in another record year for product revenues for the Company.”

The Company expects full-year 2022 product revenue will be in the range of $157-$164 million, representing strong growth of approximately 20%-25% compared to preliminary unaudited 2021 full-year product revenue of $130.9 million.

“In addition to the commercial momentum that we expect will continue in 2022, we have several exciting initiatives on tap that we believe will extend our leadership position in transfusion medicine globally,” continued Greenman. “We remain committed to balancing these investments in these initiatives in the future with the financial discipline necessary to potentially achieve cash flow breakeven.”

Finally, Cerus is beginning the nationwide launch early for INTERCEPT Fibrinogen Complex after one of the Company’s blood center production partners, Gulf Coast Regional Blood Center, received its Biological License Application (BLA) approval from U.S. Food and Drug Administration (FDA).

“As the launch of INTERCEPT Fibrinogen Complex continues in 2022, I am pleased to announce that we have made strides to expand access to this new product across the U.S.,” added Greenman. “The receipt of the first BLA approval was sooner than we expected and we are excited about IFC’s potential to drive growth for us over the next several years.”

Cerus will provide complete fourth quarter and full-year 2021 financial results and host a call to discuss both 2021 results and 2022 expectations in late February.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the Company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The

 

2

INTERCEPT red blood cell system is currently in late-stage clinical development. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. LOGO

Forward Looking Statements and Preliminary Product Revenue Results

Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus’ products, prospects and expected results, including statements relating to Cerus’ 2022 annual product revenue guidance and its expectation of another record year for product revenues for the Company; Cerus’ mission of making pathogen inactivation the standard of care globally; Cerus’ expectation of continuing commercial momentum in 2022 and its belief that it will extend its leadership position in transfusion medicine globally; Cerus’ ability to potentially achieve cash flow breakeven in the near-term; the continuing launch of IFC and its potential to drive growth for Cerus in 2023 and beyond; and other statements that are not historical fact. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks associated with the commercialization and market acceptance of, and customer demand for, the INTERCEPT Blood System, including the risks that Cerus may not (a) meet its 2022 annual product revenue guidance, (b) effectively continue to launch and commercialize the INTERCEPT Blood System for Cryoprecipitation, (c) grow sales globally, including in its U.S. and European markets, and/or realize expected revenue contribution resulting from its U.S. and European market agreements, (d) realize meaningful and/or increasing revenue contributions from U.S. customers in the near term or at all, particularly since Cerus cannot guarantee the volume or timing of commercial purchases, if any, that its U.S. customers may make under Cerus’ commercial agreements with these customers, (e) effectively expand its commercialization activities into additional geographies and/or (f) realize any revenue contribution from its pipeline product candidates, whether due to Cerus’ inability to obtain regulatory approval of its pipeline programs, or otherwise; risks associated with the

 

3

ultimate duration and severity of the COVID-19 pandemic and resulting global economic and financial disruptions, and the current and potential future negative impacts to Cerus’ business operations and financial results such as the current and potential additional disruptions to the U.S. and EMEA blood supply resulting from the evolving effects of the COVID-19 pandemic; risks associated with Cerus’ lack of commercialization experience with the INTERCEPT Blood System for Cryoprecipitation and in the United States generally, and its ability to develop and maintain an effective and qualified U.S.-based commercial organization, as well as the resulting uncertainty of its ability to achieve market acceptance of and otherwise successfully commercialize the INTERCEPT Blood System in the United States, including as a result of licensure requirements that must be satisfied by U.S. customers prior to their engaging in interstate transport of blood components processed using the INTERCEPT Blood System; risks related to Fresenius Kabi’s efforts to assure an uninterrupted supply of platelet additive solution (PAS); risks related to how any future PAS supply disruption could affect INTERCEPT’s acceptance in the marketplace; risks related to how any future PAS supply disruption might affect current commercial contracts; risks related to Cerus’ ability to demonstrate to the transfusion medicine community and other health care constituencies that pathogen reduction, including IFC for the treatment and control of bleeding, and the INTERCEPT Blood System is safe, effective and economical; risks related to the uncertain and time- consuming development and regulatory process, including the risks that (a) Cerus may be unable to comply with the FDA’s post-approval requirements for the INTERCEPT Blood System, including by successfully completing required post-approval studies, which could result in a loss of U.S. marketing approval(s) for the INTERCEPT Blood System, (b) manufacturing site Biologics License Applications necessary for Cerus to distribute the INTERCEPT Blood System for Cryoprecipitation may not be obtained in a timely manner or at all, and (c) Cerus may be unable to obtain the requisite regulatory approvals to advance its pipeline programs and bring them to market in a timely manner or at all; risks related to product safety, including the risk that the septic platelet transfusions may not be avoidable with the INTERCEPT Blood System; risks related to adverse market and economic conditions, including continued or more severe adverse fluctuations in foreign exchange rates and/or continued or more severe weakening in economic conditions resulting from the evolving effects of the COVID-19 pandemic or otherwise in the markets where Cerus currently sells and is anticipated to sell its products; Cerus’ reliance on third parties to market, sell,

 

4

distribute and maintain its products; Cerus’ ability to maintain an effective, secure manufacturing supply chain, including the risks that (a) Cerus’ supply chain could be negatively impacted as a result of the evolving effects of the COVID-19 pandemic, (b) Cerus’ manufacturers could be unable to comply with extensive FDA and foreign regulatory agency requirements, and (c) Cerus may be unable to maintain its primary kit manufacturing agreement and its other supply agreements with its third party suppliers; Cerus’ ability to identify and obtain additional partners to manufacture the INTERCEPT Blood System for Cryoprecipitation; risks associated with Cerus’ ability to access additional funds under its term loan facility and revolving line of credit and to meet its debt service obligations, and its need for additional funding; the impact of legislative or regulatory healthcare reforms that may make it more difficult and costly for Cerus to produce, market and distribute its products; risks related to future opportunities and plans, including the uncertainty of Cerus’ future capital requirements and its future revenues and other financial performance and results, as well as other risks detailed in Cerus’ filings with the Securities and Exchange Commission, including under the heading “Risk Factors” in Cerus’ Quarterly Report on Form 10-Q, filed with the SEC on November 2, 2021, and future filings and reports by Cerus. In addition, to the extent that the COVID-19 pandemic adversely affects Cerus’ business and financial results, it may also have the effect of heightening many of the other risks and uncertainties described above. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

This press release includes Cerus’ preliminary product revenue results for the quarter and year ended December 31, 2021. Cerus is currently in the process of finalizing its full financial results for the quarter and year ended December 31, 2021, and the preliminary product revenue results presented in this press release are based only upon preliminary information available to Cerus as of January 10, 2022. Cerus’ preliminary product revenue results should not be viewed as a substitute for full audited financial statements prepared in accordance with U.S. GAAP, and undue reliance should not be placed on Cerus’ preliminary product revenue results. In addition, Cerus’ independent registered public accounting firm has not audited or reviewed the preliminary product revenue results included in this press release or expressed any opinion or other form of assurance on such preliminary product revenue results. In addition, items or events may be identified or occur after the date

 

5

hereof due to the completion of operational and financial closing procedures, final audit adjustments and other developments may arise that would require Cerus to make material adjustments to the preliminary product revenue results included in this press release. Therefore, the preliminary product revenue results included in this press release may differ, perhaps materially, from the product revenue results that will be reflected in Cerus’ audited consolidated financial statements for the year ended December 31, 2021.

Contact:

Matt Notarianni – Senior Director, Investor Relations

Cerus Corporation

925-288-6137

 

6

EX-101.SCH 3 cers-20220110.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cers-20220110_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 cers-20220110_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g286874g0108151027674.jpg GRAPHIC begin 644 g286874g0108151027674.jpg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end GRAPHIC 7 g286874g0108151027899.jpg GRAPHIC begin 644 g286874g0108151027899.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document and Entity Information
Jan. 10, 2022
Cover [Abstract]  
Entity Registrant Name CERUS CORP
Amendment Flag false
Entity Central Index Key 0001020214
Document Type 8-K
Document Period End Date Jan. 10, 2022
Entity Incorporation State Country Code DE
Entity File Number 000-21937
Entity Tax Identification Number 68-0262011
Entity Address, Address Line One 1220 Concord Ave
Entity Address, Address Line Two Suite 600
Entity Address, City or Town Concord
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94520
City Area Code (925)
Local Phone Number 288-6000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol CERS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 d286874d8k_htm.xml IDEA: XBRL DOCUMENT 0001020214 2022-01-10 2022-01-10 CERUS CORP false 0001020214 8-K 2022-01-10 DE 000-21937 68-0262011 1220 Concord Ave Suite 600 Concord CA 94520 (925) 288-6000 false false false false Common Stock, par value $0.001 per share CERS NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

M-8?20$3;8T.P6BP^0"X99K>]9!:GH_ M 0 / ( \ !X;"]W;W)K8F]O:RYX;6R-49:EL@9OTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+D6M#V743&4K& M& 3L@!W".?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+)+S$P,9M2XK. M%7HR#'9 C.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\@2P/73>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0 ( !Q!*E0D M'INBK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T. M@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4 M=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[N MF:*'3^ 5!+ P04 " < M02I499!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0 MA:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS> MCQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[ ME.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8: M8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X M(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA M/UY_ 5!+ 0(4 Q0 ( !Q!*E0'04UB@0 +$ 0 " M 0 !D;V-0&UL4$L! A0#% @ '$$J5+4TY'CN M*P( !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! A0# M% @ '$$J5)E&PO=V]R:W-H965T&UL4$L! A0# M% @ '$$J5)^@&_"Q @ X@P T ( !@0P 'AL+W-T M>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% M @ '$$J5"0>FZ*M ^ $ !H ( !LA$ 'AL+U]R96QS M+W=O9(9 0 SP, M !, ( !EQ( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& / D "0 ^ @ X1, end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d286874d8k.htm cers-20220110.xsd cers-20220110_lab.xml cers-20220110_pre.xml d286874dex991.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d286874d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d286874d8k.htm" ] }, "labelLink": { "local": [ "cers-20220110_lab.xml" ] }, "presentationLink": { "local": [ "cers-20220110_pre.xml" ] }, "schema": { "local": [ "cers-20220110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cers", "nsuri": "http://www.cerus.com/20220110", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d286874d8k.htm", "contextRef": "duration_2022-01-10_to_2022-01-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d286874d8k.htm", "contextRef": "duration_2022-01-10_to_2022-01-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.cerus.com//20220110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001193125-22-005117-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-005117-xbrl.zip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end